Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ: SAGE )

7.020 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.32% to 37,678.27 while the NASDAQ fell 1.16% to 15,681.95. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data
Sage Therapeutics' Phase 2 study on dalzanemdor (SAGE-718) for mild cognitive impairment in Parkinson's Disease. Learn about topline results, safety, and future milestones in 2024. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark
Safe Therapeutics emphasized it's still testing the same drug in patients with Alzheimer's and Huntington's diseases. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Demystifying Sage Therapeutics: Insights From 5 Analyst Reviews
Via Benzinga
Peeling Back The Layers: Exploring Sage Therapeutics Through Analyst Insights
Via Benzinga
Earnings Scheduled For February 14, 2024
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion. 
Via Benzinga
J B Hunt Transport Reports Downbeat Earnings, Joins ASML And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at Upcoming March Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
The Latest Analyst Ratings for Sage Therapeutics
Via Benzinga
Analyst Ratings for Sage Therapeutics
Via Benzinga
These Analysts Boost Their Forecasts On Sage Therapeutics Following Q4 Results
Sage Therapeutics, Inc. (NASDAQ: SAGE) reported better-than-expected fourth-quarter revenue results on Wednesday. 
Via Benzinga
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Why Sage Therapeutics Stock Sank Today
A secondary stock sale and underwhelming quarterly results sent investors to the off-ramp. 
Via The Motley Fool
Sage Therapeutics Announces Changes to Board of Directors
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
From Sage Therapeutics, Inc.
Via Business Wire
5 Biotech stocks tapping into unmet mental health treatment needs
Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments. 
Via MarketBeat
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
From Sage Therapeutics, Inc.
Via Business Wire
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
From Biogen Inc.
Via GlobeNewswire
Sage Therapeutics to Present at Upcoming November Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
From Sage Therapeutics, Inc.
Via Business Wire
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry. 
Via Benzinga
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.